Cargando…
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are...
Autores principales: | Geier, Brian, Kurmashev, Dias, Kurmasheva, Raushan T., Houghton, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549564/ https://www.ncbi.nlm.nih.gov/pubmed/26380223 http://dx.doi.org/10.3389/fonc.2015.00193 |
Ejemplares similares
-
Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing
por: Ghilu, Samson, et al.
Publicado: (2021) -
Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019) -
Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma
por: Ghilu, Samson, et al.
Publicado: (2022) -
PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models
por: Yang, Juechen, et al.
Publicado: (2020) -
PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma
por: Del Pozo, Vanessa, et al.
Publicado: (2021)